<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To assess the frequency and clinical characteristics of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) oral toxicity in <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (RA) patients, 51 RA patients receiving MTX and 46 RA patients not receiving MTX were studied </plain></SENT>
<SENT sid="1" pm="."><plain>A questionnaire, the credibility of which was tested on four separate patient groups including a group with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's Syndrome</z:e>, was used as a tool to determine the prevalence of <z:hpo ids='HP_0010280'>stomatitis</z:hpo> by a blind observer </plain></SENT>
<SENT sid="2" pm="."><plain>In this first controlled study of the oral toxicity of MTX, prevalence of <z:hpo ids='HP_0010280'>stomatitis</z:hpo> was found in 37.2% in the group taking MTX and 19.5% in the group not taking MTX (P = 0.054) </plain></SENT>
<SENT sid="3" pm="."><plain>No statistical differences were detected with respect to number, duration, frequency, and site of <z:hpo ids='HP_0010280'>stomatitis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Two of the 51 MTX taking patients temporarily reduced their MTX dosage and only one patient temporarily terminated MTX treatment </plain></SENT>
<SENT sid="5" pm="."><plain>MTX and toxicity is usually of no major clinical concern in the treatment of RA </plain></SENT>
</text></document>